Clinical Trial: Comparison of DOACs and LMWH for Thromboprophylaxis After Total Knee Arthroplasty

U.S., Oct. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07869615) titled 'Comparison of DOACs and LMWH for Thromboprophylaxis After Total Knee Arthroplasty' on Oct. 04.

Brief Summary: Yes. For these two fields, I would enter the following in English, based on your study protocol.

1. Brief Summary

Copy and paste:

This study aims to compare three thromboprophylaxis regimens in adults undergoing primary total knee arthroplasty: rivaroxaban 10 mg once daily, apixaban 2.5 mg twice daily, and low-molecular-weight heparin (LMWH) once daily. The study will assess venous blood flow in the lower limbs using Doppler ultrasound and determine whether blood flow differs between the three treatment groups. Participan...